NEW YORK (GenomeWeb) – BioDiscovery announced today that it has signed a collaborative agreement to provide its NxClinical data visualization software to Illumina.
Under the terms of the agreement, NxClinical will be the secondary data analysis and management tool for Illumina's CytoSeq assay. The software will be offered as an interactive tool for visualization and interpretation of genomic events, the firms said, and will directly read CytoSeq results to process data and provide results.
Financial and other details were not disclosed.
"The software's ability to handle different types of data such as copy number variation, allelic events, and sequence variants makes it an ideal tool for CytoSeq," BioDiscovery President Soheil Shams said in a statement. "NxClinical was designed to provide reliability and consistency in the analysis and reporting of genomic events and encompasses many automated features that increase efficiency and eliminate repetitive tasks."
Illumina's next-generation sequencing-based CytoSeq assay provides researchers with data on copy number variation, absence of heterozygosity, and single nucleotide variation.
In the past, BioDiscovery has partnered with other firms to market its software, including Akesogen and Affymetrix.